Tapinarof

Catalog No.S9700 Synonyms: GSK2894512, Benvitimod, WBI 1001, DHPS, DMVT 505

For research use only.

Tapinarof (GSK2894512, Benvitimod, WBI 1001, DHPS, DMVT 505) is a natural agonist of aryl hydrocarbon receptor (AhR) and induces nuclear translocation of AhR in immortalized keratinocytes (HaCaT) with EC50 of 0.16 nM. Tapinarof induces cellular apoptosis in CD4+ T cells in a dosedependent manner with IC50 of 5.2 μM.

Tapinarof Chemical Structure

CAS No. 79338-84-4

Purity & Quality Control

Choose Selective AhR Inhibitors

Biological Activity

Description Tapinarof (GSK2894512, Benvitimod, WBI 1001, DHPS, DMVT 505) is a natural agonist of aryl hydrocarbon receptor (AhR) and induces nuclear translocation of AhR in immortalized keratinocytes (HaCaT) with EC50 of 0.16 nM. Tapinarof induces cellular apoptosis in CD4+ T cells in a dosedependent manner with IC50 of 5.2 μM.
Targets
AhR [1]
(in immortalized keratinocytes)
apoptosis [1]
(in CD4+ T cells)
0.16 nM(EC50) 5.2 μM
In vitro

Tapinarof binds and activates AhR in multiple cell types, including cells of the target tissue –human skin. In addition, tapinarof moderates proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impacts barrier gene expression in primary human keratinocytes; both of these processes are likely to be downstream of AhR activation based on current evidence.[1]

In vivo

The anti-inflammatory properties of tapinarof derive from AhR agonism is conclusively demonstrated using the mouse model of imiquimod-induced psoriasiform skin lesions. Topical treatment of AhR-sufficient mice with tapinarof leads to compound-driven reductions in erythema, epidermal thickening and tissue cytokine levels. In contrast, tapinarof has no impact on imiquimod-induced skin inflammation in AhR-deficient mice.[1]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: HaCaT cells
  • Concentrations: 0.01 pM - 1 μM
  • Incubation Time: 30 min
  • Method:

    HaCaT cells (10,000 cells/well) are cultured in 96-well plates in 100 μL DMEM with HEPES, Glutamax and 10% FBS to confluence. Media is replaced with 100 μl media containing 0.2% heat-inactivated, charcoal-stripped FBS and incubated overnight. Titrating concentrations of tapinarof are added for 30 minutes followed by washing and fixing in ice-cold methanol:acetone (50:50). Samples are blocked with 3% BSA for 1 hour, then washed again in PBS with 0.1% Tween-20. Next, cells are stained with 50μL of 1:50 dilution anti-AhR antibody in 3% BSA, followed by 50 μl secondary antibody in 3% BSA/PBS.

  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 51 mg/mL
(200.53 mM)
Ethanol 51 mg/mL
(200.53 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 254.32
Formula

C17H18O2

CAS No. 79338-84-4
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05172726 Recruiting Drug: tapinarof cream 1% Plaque Psoriasis Dermavant Sciences Inc. December 2 2021 Phase 3
NCT05186805 Recruiting Drug: Tapinarof cream 1% Atopic Dermatitis Dermavant Sciences Inc. October 29 2021 Phase 2
NCT04634695 Recruiting -- Pregnancy Malaria Obafemi Awolowo University|University of Copenhagen|LSHTM|European and Developing Countries Clinical Trials Partnership (EDCTP) August 10 2020 --
NCT04042103 Completed Drug: Tapinarof cream 1% Plaque Psoriasis Dermavant Sciences GmbH|Dermavant Sciences Inc. July 23 2019 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Tapinarof | Tapinarof supplier | purchase Tapinarof | Tapinarof cost | Tapinarof manufacturer | order Tapinarof | Tapinarof distributor